The FDA has granted 510(k) marketing clearance for Haemonetics’ NexSys plasma-collection system that customizes the collection based on an individual’s body composition.

The clearance, which includes the company’s proprietary Persona technology, was backed by data from a large multicenter trial that showed the collection system yielded a greater average volume of plasma collected per donation.

Plasma-derived medicines are used to treat hundreds of conditions, such as immunodeficiency and hemophilia.